Comparative Pharmacology
Head-to-head clinical analysis: DEXFERRUM versus FERNDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXFERRUM versus FERNDEX.
DEXFERRUM vs FERNDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy; provides iron for hemoglobin synthesis and erythropoiesis in iron-deficiency states.
Ferndex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
100 mg intravenously over 2-5 minutes; may repeat if indicated (total dose depends on iron deficit).
Adults: 100 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 2.3–3.5 hours in adults with normal renal function. Closely follows iron kinetics; clinical effect persists beyond half-life due to intracellular iron utilization.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged to 24-30 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
Primarily renal: ~60% as intact drug; ~20% as metabolites. Biliary/fecal: ~15% as metabolites. Unchanged drug in feces <5%.
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <10%.
Category C
Category C
Iron Supplement
Iron Supplement